Advanced NanoTherapies
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2903 Bunker Hill Ln, Los Gatos, Californ...Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Advanced NanoTherapies
Advanced NanoTherapies is a clinical-stage life sciences company developing a specialized nanoparticle-based drug delivery platform designed for use in catheter-based vascular interventions. The company focuses on enabling localized and controlled therapeutic delivery directly at treatment sites through functionalized nanoparticles capable of carrying multiple drugs simultaneously. Its lead technology, SirPlux Duo, represents a next-generation drug-coated balloon approach that aims to enhance vascular treatment outcomes by delivering synergistic therapies in a sustained and targeted manner during minimally invasive procedures. The platform is based on intellectual property licensed from Cleveland Clinic and is being evaluated in clinical research settings, including studies assessing its safety and performance in vascular disease treatment, with regulatory recognition supporting its potential as an innovative therapeutic advancement.Explore more
Advanced NanoTherapies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Advanced NanoTherapies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Advanced NanoTherapies, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Advanced NanoTherapies has new funding data
Check if Advanced NanoTherapies has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Advanced NanoTherapies launches new products
Check out if Advanced NanoTherapies is spiking on competitors!
Click to see if Advanced NanoTherapies had a recent Job posting/layoffs
Earning: See what the market has to say on Advanced NanoTherapies recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Advanced NanoTherapies
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Advanced NanoTherapies
Compare insights from companies similar to Advanced NanoTherapies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Advanced NanoTherapies
<$5M
1-10
Private
$47.5M
2018
FP
Frank ProchVice President, Research & Development
Company Profile Activity
Activity Insights
Advanced NanoTherapies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Advanced NanoTherapies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Advanced NanoTherapies.
Advanced NanoTherapies financials insights
Gather financial insights about Advanced NanoTherapies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$5.3M
2023
Series A
$11.2M
2026
Series B
$31M
Advanced NanoTherapies Tech Stack
A closer look at the technologies used by Advanced NanoTherapies
Most Recent Scoops
Funding
Funding
Project
Spending/Investment
Funding
Funding
Advanced NanoTherapies News & Media
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications. SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech...ADVANCED NANOTHERAPIES ANNOUNCES POSITIVE RESULTS IN ITS FIRST-IN-HUMAN TRIAL AND PLANS FOR U.S. EARLY FEASIBILITY STUDY FOR SIRPLUX™ DUO DRUG-COATED BALLOON
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 /PRNewswire/ -- Advanced NanoTherapies...Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)
Milestone achieved as company announces successful enrollment of ten patients in its First-In-Human (FIH) Trial, ADVANCE-DCB LOS GATOS, Calif., Aug. 22, 2023 /PRNewswire/ -- Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company committed to solving the most...Advanced NanoTherapies Receives $7.2M
LOS GATOS, CA, Advanced NanoTherapies today announced the closing of its oversubscribed $7.2 million Series A equity financing round.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Advanced NanoTherapies
Sign Up For FreeTo access detailed company insights
Advanced NanoTherapies is a clinical-stage life sciences company developing a specialized nanoparticle-based drug delivery platform designed for use in catheter-based vascular interventions. The company focuses on enabling localized and controlled therapeutic delivery directly at treatment sites through functionalized nanoparticles capable of carry... Read More
